XENE

Xenon Pharmaceuticals Inc

XENE, USA

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada. Its product candidates include Azetukalner, a selective Kv7 potassium channel opener in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

https://www.xenon-pharma.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
XENE
stock
XENE

Xenon Pharmaceuticals Inc. $XENE is Braidwell LP's 7th Largest Position MarketBeat

Read more →
XENE
stock
XENE

Xenon Pharmaceuticals (NASDAQ:XENE) Given New $48.00 Price Target at Wells Fargo & Company Defense World

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$55.1916

Analyst Picks

Strong Buy

14

Buy

5

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

6.24

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-16.25 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-14.95 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very High

0.09

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 100.23% of the total shares of Xenon Pharmaceuticals Inc

1.

FMR Inc

(11.5223%)

since

2025/06/30

2.

venBio Select Advisor LLC

(7.0034%)

since

2025/06/30

3.

BlackRock Inc

(6.9584%)

since

2025/06/30

4.

Driehaus Capital Management LLC

(5.623%)

since

2025/06/30

5.

American Funds SMALLCAP World A

(4.9609%)

since

2025/06/30

6.

BRAIDWELL LP

(4.6754%)

since

2025/06/30

7.

HHG PLC

(4.64%)

since

2025/06/30

8.

Capital Research & Mgmt Co - Division 3

(4.1262%)

since

2025/06/30

9.

COMMODORE CAPITAL LP

(3.9232%)

since

2025/06/30

10.

Polar Capital Holdings PLC

(3.5059%)

since

2025/06/30

11.

Wellington Management Company LLP

(2.8205%)

since

2025/06/30

12.

Vestal Point Capital LP

(2.5938%)

since

2025/06/30

13.

Polar Capital Biotech S Inc

(2.5938%)

since

2025/07/31

14.

iShares Russell 2000 ETF

(2.3791%)

since

2025/08/31

15.

Holocene Advisors, LP

(2.3467%)

since

2025/06/30

16.

Strategic Advisers Fidelity US TtlStk

(2.2892%)

since

2025/07/31

17.

Vanguard Health Care Inv

(2.0746%)

since

2025/06/30

18.

AllianceBernstein L.P.

(1.9694%)

since

2025/06/30

19.

Pictet Asset Manangement SA

(1.9122%)

since

2025/06/30

20.

State Street Corp

(1.7903%)

since

2025/06/30

21.

Deep Track Capital, LP

(1.7508%)

since

2025/06/30

22.

Adage Capital Partners Gp LLC

(1.6732%)

since

2025/06/30

23.

Fidelity Select Health Care

(1.6601%)

since

2025/07/31

24.

JPMorgan Chase & Co

(1.6297%)

since

2025/06/30

25.

Westfield Capital Management Company, L.P.

(1.4948%)

since

2025/06/30

26.

Affinity Asset Advisors, LLC

(1.4266%)

since

2025/06/30

27.

Fidelity Small Cap Index

(0.9888%)

since

2025/06/30

28.

Fidelity Advisor Health Care I

(0.9597%)

since

2025/07/31

29.

Fidelity Advisor Biotechnology I

(0.9218%)

since

2025/07/31

30.

iShares Russell 2000 Growth ETF

(0.8659%)

since

2025/08/31

31.

Polar Capital Healthcare Opports Inc

(0.8458%)

since

2025/07/31

32.

Pictet-Biotech P USD

(0.8113%)

since

2025/05/31

33.

Pictet-Global Megatrend Sel I USD

(0.7205%)

since

2025/05/31

34.

JPMorgan Small Cap Growth A

(0.6972%)

since

2025/07/31

35.

American Century U.S. Small Cap Growth

(0.6936%)

since

2025/06/30

36.

American Century Small Cap Growth Inv

(0.6936%)

since

2025/06/30

37.

Fidelity Stock Selector Small Cap

(0.6846%)

since

2025/06/30

38.

Janus Henderson Triton D

(0.6682%)

since

2025/06/30

39.

Janus Henderson US SMID Cap Growth MA

(0.6682%)

since

2025/06/30

40.

Janus Henderson US SMID Cap Growth

(0.6682%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-1.21

Latest Release

Date

2025-09-30

EPS Actual

-1.15

EPS Estimate

-1.15

EPS Difference

0

Surprise Percent

0%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(3)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2.5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(2.5)
Value
Overpriced(3)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.